July 21, 2014
/PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today that it has received approval from the Israeli Ministry of Health (MOH) for PIXUVRI
is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL) who have received not more than three previous courses of treatment. The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.
, PIXUVRI will be distributed and marketed by the Neopharm Group,
second largest pharmaceuticals and health products marketer, once PIXUVRI is included in the Israeli National Health Basket of drugs by the MOH.
"The approval of PIXUVRI in
provides patients with aggressive B-cell NHL who have failed second- or third-line therapy a new approved option, where none existed before, that can effectively treat their disease with manageable side effects," said
, M.D., Faculty of Medicine at
Tel Aviv University
and Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer,
. "Patients who have relapsed after second-line therapy have a poor survival outcome. It is vital to have additional treatment options available, like PIXUVRI, so we can provide these patients the best care possible and help them battle their disease."
"We are pleased to continue to expand the availability of PIXUVRI as interest in this new therapy continues to grow," said
James A. Bianco
, M.D., President and Chief Executive Officer of CTI. "We feel PIXUVRI fills an important role in the treatment paradigm for patients with aggressive B-cell NHL, and we are focused on increasing access to the treatment for as many patients as possible."
Separately, the Dutch Healthcare Authority (NZa) and the healthcare insurance board College voor zorgverzekeringen (CVZ) of
have approved funding for PIXUVRI as an add-on drug for patients who need a third- or fourth-line treatment option for aggressive B-cell lymphoma. This follows the inclusion of PIXUVRI on the HOVON (Haemato Oncology Foundation for Adults in
) treatment guidelines, effective
June 1, 2014
. The inclusion on the Dutch list of reimbursed drugs makes PIXUVRI the first registered and reimbursed medicine for the treatment of patients with multiply relapsed or refractory aggressive B-cell NHL in
About PIXUVRI® (pixantrone)
PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Unlike related compounds, PIXUVRI forms stable DNA adducts and in preclinical models has superior anti-lymphoma activity compared to related compounds. PIXUVRI was structurally designed so that it cannot bind iron and perpetuate oxygen radical production or form a long-lived hydroxyl metabolite -- both of which are the putative mechanisms for anthracycline-induced acute and chronic cardiotoxicity. These novel pharmacologic properties allow PIXUVRI to be administered to patients with near maximal lifetime exposure to anthracyclines without unacceptable rates of cardiotoxicity.